FDA Proposes Criteria For Allowing Bulk Compounding To Address Unmet Clinical Need

FDA’s draft guidance spells out criteria for which bulk drug substances outsourcing facilities can use to address unmet clinical needs, yet uncertainty lingers as to whether the draft guidance resolves a pending lawsuit.